Value Adjusted for Debt and Cash: Akero Therapeutics (AKRO)

Brandmark of Akero Corp (AKRO)

Akero Therapeutics' efficiency relies on the success of Efruxifermin testing, the control of development costs, and strategic alliances. This chart of the company's valuation history is currently at 3762.12. The business focuses on creating innovative treatments for liver pathologies, where the ability to stop fibrosis could secure leadership in the premium medical segment.

akerotx.com (AKRO) Total Company Value: for the period 11/23/2025 - 12/20/2025

Akero Therapeutics (AKRO) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price Akero Therapeutics, Inc.|AKRO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Akero Therapeutics|AKRO - Total Company Value
- book capitalization information:
Net Asset Value per Share Akero Therapeutics|AKRO - Company Book Value|Market Capitalization to Net Assets akerotx.com|AKRO - Company Total Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Akero Therapeutics|AKRO - Long-Term Debt to Capital|Short-Term Debt to Capital akerotx.com|AKRO - Company Debts|Debt to Net Assets Ratio Akero Therapeutics|AKRO - Company Long-Term Debt|Company Current Liabilities Akero Therapeutics|Quick Ratio akerotx.com
- earnings and market multiples details:
AKRO - Net Income
Analysis of all company metrics:Akero Therapeutics, Inc.
Brand item of Akero Therapeutics

The resilience of Akero Therapeutics (AKRO) to market volatility depends directly on the development costs of efruxifermin and the prospects of FDA approval. By analyzing changes in Enterprise Value (EV), an investor can determine the actual acquisition price of the business via the sum of market capitalization and net debt, allowing for an assessment of the company's fundamental value without the distortions typical of simple share prices.

Competitors of Akero Therapeutics (AKRO)

Enterprise Value Ascendis Pharma AS ASND|MDGL - Total Company Value|Value Adjusted for Debt and Cash CORT (Corcept Therapeutics Corp)|Rhythm Pharmaceuticals (RYTM) - Total Company Value|Total Enterprise Value metsera.com (MTSR)|Total Company Value MoonLake|Crinetics Pharmaceuticals, Inc. - Full Business Value|Enterprise Value NAMS|SLNO (Soleno Therapeutics Corp) - Value Adjusted for Debt and Cash|Enterprise Value FOLD (Amicus Therapeutics)|Enterprise Value 89bio.com ETNB|AGIO - Total Company Value|Value Adjusted for Debt and Cash GPCR (Structure Therapeutics Inc)|MiMedx Group (MDXG) - Total Company Value|Real Price to Acquire Entire Company Rezolute Bio|LXRX (Lexicon Pharmaceuticals) - Enterprise Value|Enterprise Value mbxbio.com|Real Price to Acquire Entire Company ALT (Altimmune)|AARD (Aardvark Therapeutics Inc.) - Value Adjusted for Debt and Cash|Total Company Value Sagimet SGMT|BIOA - Real Price to Acquire Entire Company|Biomea Fusion, Inc. - Enterprise Value|Total Enterprise Value Quince Therapeutics|GUTS (Fractyl Health) - Real Price to Acquire Entire Company|VTVT: Aggregate Business Value|ATPC (Agape ATP Corp) - Enterprise Value|Enterprise Value Pluri Inc|Enterprise Value SYBX|Total Company Value LPCN (lipocine.com)|Total Company Value Matinas BioPharma Holdings MTNB|sprucebiosciences.com (SPRB) - Total Enterprise Value|GLTO - Total Company Value|CTCX: Total Company Value|LUMO: Enterprise Value|ONVO - Company Buyout Price|Total Company Value Radius Recycling